AML   

Does your answer change based on clinical or molecular risk factors, and if so how? Does your answer change if MRD status after induction is unknown?

Is there a role for non-myeloablative regimens?

Have you changed your practice given BMT-CTN 1506/Morpho results? Would you utilize maintenance therapy in patients who achieve MRD- remission?

How does graft source, conditioning regimen, and indication for transplant affect your decision regarding G-CSF?

NGS results are pending

Would you test for bone marrow failure syndromes before beginning the conditioning regimen?

Do you re-challenge them? If so, what pre-medications do you give? Do you dose reduce the cytarabine? Or do you switch another regimen?

It used to be a contraindication for G-CSF use for AML patients, but currently, several protocols include it to decrease neutropenic duration.

Patient treated per AAML0531

Particular patient is s/p 2 HSCTs

Or do you use prophylactic defibrotide?

I have heard <20% MRD. What about proceeding if patient is hypoplastic after chemotherapy?

Should the goal always be to proceed to a second transplant? 

Would you consider “bridging” therapy with something like an HMA?

Does acute leukemia sub-type affect your decision?